Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Vivian M. Liu, Megan Othus, Rhonda E. Ries, Jasmine Naru, Era L. Pogosova-Agadjanyan, Frederick R. Appelbaum, Lan W. Beppu, Thomas R. Chauncey, Harry P. Erba, John E. Godwin, Matthew Fitzgibbon, Min Fang, Stanley C. Lee, Anna B. Moseley, Jerald P. Radich, Cheryl L. Willman, Feinan Wu, Soheil Meshinchi, Derek L. Stirewalt

Blood (2024) 144 (Supplement 1): 4309.

https://doi.org/10.1182/blood-2024-198506

Published: 2024

Journal Articles

Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome

Courtnee A. Clough, Joseph Pangallo, Martina Sarchi, Janine O. Ilagan, Khrystyna North, Rochelle Bergantinos, Massiel C. Stolla, Jasmine Naru, Patrick Nugent, Eunhee Kim, Derek L. Stirewalt, Arvind R. Subramaniam, Omar Abdel-Wahab, Janis L. Abkowitz, Robert K. Bradley, Sergei Doulatov

Blood (2022) 139 (13): 2038–2049.

https://doi.org/10.1182/blood.2021012652

Published: 2022

Includes: Supplemental data

Journal Articles

MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis

Blood (2022) 139 (5): 761–778.

https://doi.org/10.1182/blood.2021011802

Published: 2022

Includes: Supplemental data

Journal Articles

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study

Anna B. Halpern, MD, Sarah A. Buckley, MD, Megan Othus, PhD, Emily M Huebner, Kaysey F. Orlowski, Bart L Scott, MD, Andrea M. Perdue, PA-C, Heather A. Smith, PA-C, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Stephanie Cassone, MSN, FNP-BC, Tara L. Chen, PharmD, BCOP, Derek L. Stirewalt, Elihu H. Estey, MD, Roland B. Walter, MD PhD

Blood (2016) 128 (22): 1064.

https://doi.org/10.1182/blood.V128.22.1064.1064

Published: 2016

Journal Articles

MS4A3: A New Player in Leukemic Stem Cell Survival in Chronic Myeloid Leukemia

Anna M. Eiring, PhD, Jamshid S. Khorashad, MD PhD, Anupriya Agarwal, PhD, Clinton C. Mason, PhD, Russell Bell, PhD, Anna Senina, MS, Anthony D. Pomicter, MS, Fan Yu, MD, Hannah M. Redwine, Amber D. Bowler, Phillip M. Clair, MS, Srinivas K. Tantravahi, MD, Shannon K. McWeeney, Brian J. Druker, MD, Derek L. Stirewalt, Vivian Oehler, MD, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2016) 128 (22): 934.

https://doi.org/10.1182/blood.V128.22.934.934

Published: 2016

Journal Articles

Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report

Era L. Pogosova-Agadjanyan, Anna Moseley, Brent L. Wood, MD PhD, Frederick R. Appelbaum, Thomas Chauncey, I-Ming L. Chen, DVM, MS, Harry P. Erba, MD PhD, John E. Godwin, Min Fang, Kenneth J. Kopecky, Alan F. List, Megan Othus, Jerald P. Radich, Cheryl L. Willman, Soheil Meshinchi, Derek L. Stirewalt

Blood (2016) 128 (22): 2890.

https://doi.org/10.1182/blood.V128.22.2890.2890

Published: 2016

Journal Articles

Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration

Dalia Selim, MD, Todd A. Alonzo, PhD, Megan Othus, PhD, Robert Gerbing, BS, Fabiana Ostronoff, MD, Katherine Tarlock, MD, Matthew A. Kutny, MD, Richard Aplenc, MD PhD, E. Anders Kolb, MD, Jerald P. Radich, MD, Frederick R. Appelbaum, MD, Alan S. Gamis, MD MPH, Derek L. Stirewalt, Soheil Meshinchi, MD PhD

Blood (2016) 128 (22): 285.

https://doi.org/10.1182/blood.V128.22.285.285

Published: 2016

Journal Articles

MS4A3 Improves Imatinib Response and Survival in BCR-ABL1 Primary TKI Resistance and in Blastic Transformation of Chronic Myeloid Leukemia

Anna M. Eiring, PhD, Jamshid S. Khorashad, MD PhD, Anupriya Agarwal, PhD, Clinton C. Mason, PhD, Fan Yu, MD, Hannah M. Redwine, Amber D. Bowler, Kevin C. Gantz, Kimberly R. Reynolds, MS, Phillip M. Clair, MS, David J. Anderson, MBA, Srinivas K Tantravahi, Shannon K. McWeeney, PhD, Brian J. Druker, MD, Derek L. Stirewalt, MD, Vivian G. Oehler, MD, Thomas O'Hare, PhD, Michael W. Deininger

Blood (2015) 126 (23): 14.

https://doi.org/10.1182/blood.V126.23.14.14

Published: 2015

Journal Articles

Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106

Fabiana Ostronoff, MD, Todd A. Alonzo, PhD, Megan Othus, PhD, Matthew A. Kutny, MD, Robert B. Gerbing, MA, Jerald P. Radich, MD, Harry P Erba, MD PhD, Frederick R. Appelbaum, MD, E. Anders Kolb, MD, Alan S. Gamis, MD MPH, Derek L. Stirewalt, MD, Soheil Meshinchi, MD PhD

Blood (2015) 126 (23): 2576.

https://doi.org/10.1182/blood.V126.23.2576.2576

Published: 2015

Journal Articles

Sample Processing Obscures Cancer-Specific Alterations in Leukemic Transcriptomes

Heidi Dvinge, PhD, Rhonda E. Ries, MA, Janine O. Ilagan, PhD, Derek L. Stirewalt, MD, Soheil Meshinchi, MD PhD, Robert K. Bradley, PhD

Blood (2014) 124 (21): 2201.

https://doi.org/10.1182/blood.V124.21.2201.2201

Published: 2014

Journal Articles

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study

Anna B. Halpern, MD, Elihu H. Estey, MD, Megan Othus, PhD, Kaysey F. Orlowski, Morgan A. Powell, BS, Tara L. Chen, PharmD, Pamela S. Becker, MD PhD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Fabiana Ostronoff, MD, Elizabeth M. Ranker, PA-C, Mazyar Shadman, MD MPH, Derek L. Stirewalt, MD, Roland B. Walter, MD PhD MS

Blood (2014) 124 (21): 3730.

https://doi.org/10.1182/blood.V124.21.3730.3730

Published: 2014

Journal Articles

Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report

Farhad Ravandi, MD, Megan Othus, PhD, Stefan H. Faderl, MD, Derek L. Stirewalt, MD, Sherry R. Pierce, RN, BS, Gautam Borthakur, MD, John Godwin, MD, Jeanne E. Anderson, MD, Stephen Petersdorf, MD, Jorge E. Cortes, MD, Fabiana Ostronoff, MD, Era Pogosova-Agadijanyan, MD, Frederick R. Appelbaum, MD, Hagop M. Kantarjian, MD, Elihu H. Estey, MD

Blood (2013) 122 (21): 2686.

https://doi.org/10.1182/blood.V122.21.2686.2686

Published: 2013

Journal Articles

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

Fabiana Ostronoff, MD, Megan Othus, PhD, Soheil Meshinchi, MD, PhD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Alan List, MD, Vivian G. Oehler, MD, Stephen Petersdorf, MD, Era L. Pogosova-Agadjanyan, Jerald Radich, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2013) 122 (21): 1315.

https://doi.org/10.1182/blood.V122.21.1315.1315

Published: 2013

Journal Articles

RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia

Fabiana Ostronoff, MD, Matthew Fitzgibbon, Martin McIntosh, Rhonda E. Ries, MA, Alan S. Gamis, MD, MPH, Todd A. Alonzo, PhD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 1278.

https://doi.org/10.1182/blood.V120.21.1278.1278

Published: 2012

Journal Articles

Novel IL23R Splice Variant Is Associated with Worse Prognosis in Pediatric Patients with AML.

Derek L. Stirewalt, MD, Todd A. Alonzo, PhD, Era L. Pogosova-Agadjanyan, Robert B. Gerbing, M.A., Janet Franklin, MD, MPH, Susana C. Raimondi, Betsy A. Hirsch, PhD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 2546.

https://doi.org/10.1182/blood.V120.21.2546.2546

Published: 2012

Journal Articles

A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Blood (2012) 120 (21): 2590.

https://doi.org/10.1182/blood.V120.21.2590.2590

Published: 2012

Journal Articles

Novel IRF8 Splice Variants Are Validated As a New Prognostic Biomarker for Adverse Outcome in an Independent Population of Pediatric Patients with AML.

Derek L. Stirewalt, MD, Todd A. Alonzo, PhD, Era L. Pogosova-Agadjanyan, Robert B. Gerbing, M.A., Janet Franklin, MD, MPH, Hana Lee, Susana C. Raimondi, Betsy A. Hirsch, PhD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 2550.

https://doi.org/10.1182/blood.V120.21.2550.2550

Published: 2012

Journal Articles

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS

H. Joachim Deeg, Bart L. Scott, Min Fang, Howard M. Shulman, Boglarka Gyurkocza, David Myerson, John M. Pagel, Uwe Platzbecker, Aravind Ramakrishnan, Jerald P. Radich, Brenda M. Sandmaier, Mohamed Sorror, Derek L. Stirewalt, Wendy A. Wilson, Rainer Storb, Frederick R. Appelbaum, Ted Gooley

Blood (2012) 120 (7): 1398–1408.

https://doi.org/10.1182/blood-2012-04-423046

Published: 2012

Includes: Supplemental data

Journal Articles

Expression Differences of Prognostic Biomarkers in Mononuclear Cells (MNCs) and Malignant Blasts of Acute Myeloid Leukemia (AML) Patients

Era L. Pogosova-Agadjanyan, Soheil Meshinchi, MD, Ph.D., Hana Lee, Brent L. Wood, MD, PhD, Derek L. Stirewalt, MD

Blood (2011) 118 (21): 1468.

https://doi.org/10.1182/blood.V118.21.1468.1468

Published: 2011

Journal Articles

Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG

Era L. Pogosova-Agadjanyan, Kenneth J. Kopecky, PhD, Stephen Petersdorf, MD, Harry Paul Erba, MD, PhD, Richard M. Stone, MD, Soheil Meshinchi, MD, PhD, Thomas J. Nevill, MD, FRCPC, Jerald P. Radich, MD, Leif Stenke, MD, PhD, Marilyn L Slovak, PhD, Robert K Stuart, MD, Martin S. Tallman, MD, Cheryl L Willman, MD, Rebecca M. Mortensen, Breanna L. Wentz, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2011) 118 (21): 2520.

https://doi.org/10.1182/blood.V118.21.2520.2520

Published: 2011

NARROW

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome

MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study

MS4A3: A New Player in Leukemic Stem Cell Survival in Chronic Myeloid Leukemia

Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report

Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration

MS4A3 Improves Imatinib Response and Survival in BCR-ABL1 Primary TKI Resistance and in Blastic Transformation of Chronic Myeloid Leukemia

Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106

Sample Processing Obscures Cancer-Specific Alterations in Leukemic Transcriptomes

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study

Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia

Novel IL23R Splice Variant Is Associated with Worse Prognosis in Pediatric Patients with AML.

A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Novel IRF8 Splice Variants Are Validated As a New Prognostic Biomarker for Adverse Outcome in an Independent Population of Pediatric Patients with AML.

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS

Expression Differences of Prognostic Biomarkers in Mononuclear Cells (MNCs) and Malignant Blasts of Acute Myeloid Leukemia (AML) Patients

Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only